The COMBAT clinical trial (NCT05633160) is currently evaluating [67Cu]Cu-SAR-BBN for radioligand therapy in metastatic castration-resistant PCa patients ineligible for [177Lu]Lu-PSMA-617 due to low PSMA expression [164], offering a promising alternative for this underserved patient subset. This evidence concerns the gene FOLH1 and posterior cortical atrophy.